Skip to content
Subscriber Only

Amarin Sinks to Five-Month Low After Losing Ruling on Heart Drug

  • Company’s loss opens the door to generic-drug competition
  • Ruling came just one day after appeals court heard arguments
Updated on

Amarin Corp. fell to the lowest since March after it lost its bid to revive patents on the heart medicine Vascepa, its only product, a decision that opens the door to generic competition for the drug.

The U.S. Court of Appeals for the Federal Circuit in Washington affirmed a trial court ruling that invalidated six patents on Vascepa. The decision, made without a formal opinion, came just one day after the court heard arguments in the case.